Durability With Aflibercept 8 mg in Retinal Vascular Diseases

In “Durability with Aflibercept 8 mg in Retinal Vascular Diseases,” our panel explores how clinical trial data for aflibercept 8 mg are shaping treatment strategies across wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO). The panelists review key findings from the PULSAR, PHOTON, and QUASAR trials and discuss how extended dosing intervals with aflibercept 8 mg compare with aflibercept 2 mg in terms of visual outcomes, fluid control, and injection frequency.

Throughout the discussion, the expert faculty highlight how aflibercept 8 mg demonstrated noninferior vision outcomes with fewer injections over one and two years while also showing earlier and more robust retinal drying compared with aflibercept 2 mg. The panel discusses how improved fluid control and slower reaccumulation of retinal fluid may support longer dosing intervals and reduced treatment burden for patients. In addition, the expert faculty emphasize the importance of balancing durability with preservation of visual acuity, noting that longer intervals should not come at the expense of vision outcomes.

The panel also examines how findings from clinical trials can be translated into real-world clinical practice. The expert faculty discuss how registration studies are designed to demonstrate the capabilities of therapies under controlled conditions while also providing insights into how clinicians may apply those findings in individualized patient care. The conversation further highlights the potential role of higher-dose anti-VEGF therapy in reducing injection frequency earlier in the treatment course, particularly in diseases characterized by significant VEGF upregulation such as RVO.

Our next episode, “Real-World Experience with Aflibercept 8 mg in Retinal Vascular Diseases,” features the panelists discussing how real-world evidence is informing expectations around durability, treatment intervals, and disease control with aflibercept 8 mg. The expert faculty highlight how even modest interval extensions may significantly reduce long-term treatment burden for patients with retinal vascular diseases.